Symptoms of HR+/HER2- breast cancer can vary but often include ... In addition to genetic mutations, hormonal changes likely increase the risk of developing HR+/HER2- breast cancer.

Metastatic breast cancer is complex, requiring holistic care and ongoing treatment, with varying prognosis depending on several factors.

The American Cancer Society recommends choosing non-hormonal options to treat menopause symptoms instead ... Like PIK3CA, HER2 is not an inherited gene mutation. Most breast cancer is HER2-negative.

They're given to women who have a mutation in the BRCA gene and HER2-negative breast cancer. Capivasertib (Truqap). This drug blocks some types of the AKT protein. It can be used if the cancer ...

including exon 20 insertion mutations, in NSCLC. In NSCLC, Response to ICIs Is Influenced by EGFR- and HER2-Mutant Subtypes Patients with advanced NSCLC and EGFR-sensitizing mutations have ...

Boehringer's zongertinib and Bayer's BAY 2927088 are in phase 3 testing for advanced non-small cell lung cancer (NSCLC) with activating HER2 mutations, and the WCLC congress gave an opportunity to ...

The human epidermal growth factor receptor 2 (HER2) gene mutation is involved in 1% to 4% of NSCLCs. About 1% to 2% of NSCLCs have the ROS1 mutation. The ROS1 mutation is similar to the ALK mutation.

In the ESR1m population, treatment with vepdegestrant resulted in a statistically significant and clinically meaningful improvement in PFS compared with fulvestrant. Topline results were announced ...

Zongertinib is being reviewed for the treatment of adults with unresectable or metastatic non-small cell lung cancer (NSCLC) whose tumours have HER2 mutations and who have received prior systemic ...